lymphocytes

[Iovance Biotherapeutics, Inc.] Iovance Biotherapeutics, Inc. announced that the US FDA has allowed an IND to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.

[Cancer Science] Scientists investigated how tumor epithelial cells influenced tumor growth and immune responses of hepatocellular carcinoma focusing on CD8+ T-cell infiltration and exhaustion.

[Molecular Therapy-Nucleic Acids] Initial in silico analysis predicted exons that can be skipped with minimal loss of neurofibromin function, which was confirmed with in vitro assessments utilizing an neurofibromatosis type 1 (Nf1) cDNA-based functional screening system.

[Blood Advances] Recipients of hematopoietic stem cell transplantation showed weaker immune responses to COVID-19 vaccines than healthy controls

[Cell Death Discovery] Scientists found that the expression of the c-Myc oncogene was negatively correlated with T cell infiltration rate in osteosarcoma. Pharmacological inhibition of c-Myc with JQ-1 significantly reduced tumor burden and improved overall survival in an immunocompetent syngeneic murine model of osteosarcoma.

[Cell] Investigators found that in Tgfbr2 knockout tumors, the tumor microenvironment (TME) was converted to a fibro-mucinous state, and T cells excluded, concomitant with upregulated TGFβ and TGFβ-mediated fibroblast activation, indicating that TGFβ-receptor loss on cancer cells increased TGFβ bioavailability and its immunosuppressive effects on the TME.